Abstract
In recent years, the pharmaceutical industry has become very interested in sex as a focus for drug development and marketing. Many sexologists have embraced this new trend, particularly because of greatly welcomed research funding and increased professional opportunities. However, this new relationship may be a Faustian bargain, and certainly raises serious ethical, political, theoretical, and research problems which must be openly discussed. This paper examines background elements which have led to this new science‐industry rapprochement, discusses research and publication problems which have arisen, analyzes conflicts between the models of sexuality favored by industry and sexology, and offers advice for preventing further erosion of sexology's liberatory mission despite the threats of commercialization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
